NCI-H82Homo sapiens (Human)Cancer cell line
Also known as: NCI-H-82, H82, H-82, NCI H82, NCIH82, H82sclc
Quick Overview
Human small cell lung cancer cell line with known genetic alterations.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_1591 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Pleural effusion[UBERON:UBERON_0000175] |
Donor Information
| Age | 41 |
|---|---|
| Age Category | Adult |
| Sex | Male |
| Race | caucasian |
Disease Information
| Disease | Lung small cell carcinoma |
|---|---|
| Lineage | Lung |
| Subtype | Small Cell Lung Cancer |
| OncoTree Code | SCLC |
DepMap Information
| Source Type | ATCC |
|---|---|
| Source ID | ACH-000355_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| Gene fusion | MYH7 | PVT1-MYH7 | - | - | from parent cell line NCI-H82 |
| MutationSimple | TP53 | p.Thr125Thr (c.375G>T) | Unspecified | Impairs TP53 splicing dramatically | from parent cell line NCI-H82 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
Sellers W.R., Gygi S.P.
Cell 180:387-402.e16(2020).
From clinical specimens to human cancer preclinical models -- a journey the NCI-cell line database-25 years later.
Aldige C.R., Wistuba I.I., Minna J.D.
J. Cell. Biochem. 121:3986-3999(2020).
High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors.
Gazdar A.F., Minna J.D.
Oncogene 7:339-346(1992).
Neuromedin B is present in lung cancer cell lines.";
Giaccone G., Battey J., Gazdar A.F., Oie H.K., Draoui M., Moody T.W.
Cancer Res. 52:2732s-2736s(1992).
Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation.
Linnoila R.I.
Oncogene 7:743-749(1992).
Novel antigens characteristic of neuroendocrine malignancies.";
Boerman O.C., Ramaekers F.C.S.
Cancer 67:619-633(1991).
Metabolic activation of 4-ipomeanol in human lung, primary pulmonary carcinomas, and established human pulmonary carcinoma cell lines.
Adelberg S., Czerwinski M.J., McMahon N.A., Eggleston J.C., Boyd M.R.
J. Natl. Cancer Inst. 82:1420-1426(1990).
Spontaneous changes in intermediate filament protein expression patterns in lung cancer cell lines.
Carney D.N., Vooijs G.P., Ramaekers F.C.S.
J. Cell Sci. 91:91-108(1988).
Establishment and identification of small cell lung cancer cell lines having classic and variant features.
Moody T.W., Zweig M.H., Minna J.D.
Cancer Res. 45:2913-2923(1985).
Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties.
Gazdar A.F., Carney D.N., Nau M.M., Minna J.D.
Cancer Res. 45:2924-2930(1985).
Cytogenetics of human small cell lung cancer.";
Whang-Peng J., Lee E.C.
Recent Results Cancer Res. 97:37-46(1985).
Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.
Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.
Cancer Res. 48:589-601(1988).
Heterogeneity in the radiation survival curves and biochemical properties of human lung cancer cell lines.
Mitchell J.B.
J. Natl. Cancer Inst. 73:801-807(1984).
Monoclonal antibodies that demonstrate specificity for several types of human lung cancer.
Cuttitta F., Rosen S.T., Gazdar A.F., Minna J.D.
Proc. Natl. Acad. Sci. U.S.A. 78:4591-4595(1981).
Analysis of human small cell lung cancer differentiation antigens using a panel of rat monoclonal antibodies.
Gazdar A.F., Minna J.D.
Cancer Res. 44:2052-2061(1984).
Subcellular localization and supramolecular organization of neuroendocrine-specific protein B (NSP-B) in small cell lung cancer.
Kuijpers H.J.H., Roebroek A.J.M., van de Ven W.J.M., Ramaekers F.C.S.
Eur. J. Cell Biol. 65:341-353(1994).
Insulin-like growth factor expression in human cancer cell lines.";
Grimley C., Battey J., Mulshine J.L., Cuttitta F.
J. Biol. Chem. 271:11477-11483(1996).
NCI-Navy Medical Oncology Branch cell line data base.";
Carney D.N., Minna J.D., Mulshine J.L.
J. Cell. Biochem. Suppl. 24:32-91(1996).
MYC family DNA amplification in 126 tumor cell lines from patients with small cell lung cancer.
Ihde D.C., Gazdar A.F.
J. Cell. Biochem. Suppl. 24:210-217(1996).
Coexpression of transcripts encoding EPHB receptor protein tyrosine kinases and their ephrin-B ligands in human small cell lung carcinoma.
Tang X.X., Brodeur G.M., Campling B.G., Ikegaki N.
Clin. Cancer Res. 5:455-460(1999).
The ubiquitin-activating enzyme E1-like protein in lung cancer cell lines.
Brinker M.G.L., Ruiters M.H.J., de Leij L.F.M.H., Buys C.H.C.M.
Int. J. Cancer 85:871-876(2000).
Mutation and expression of the DCC gene in human lung cancer.";
Yokota J.
Neoplasia 2:300-305(2000).
Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.
Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.
Oncogene 19:4632-4639(2000).
Chromosome abnormalities in 10 lung cancer cell lines of the NCI-H series analyzed with spectral karyotyping.
Grigorova M., Lyman R.C., Caldas C., Edwards P.A.W.
Cancer Genet. Cytogenet. 162:1-9(2005).
Integrative genomic analysis of small-cell lung carcinoma reveals correlates of sensitivity to bcl-2 antagonists and uncovers novel chromosomal gains.
Sauter G., Lesniewski R., Semizarov D.
Mol. Cancer Res. 5:331-339(2007).
A gene-alteration profile of human lung cancer cell lines.";
Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.
Hum. Mutat. 30:1199-1206(2009).
Signatures of mutation and selection in the cancer genome.";
Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Nature 463:893-898(2010).
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Haber D.A.
Cancer Res. 70:2158-2164(2010).
Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma.
Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.
Cancer Sci. 101:1891-1896(2010).
Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors.
Lucchi M., Smith W.I. Jr., Meltzer P.S., Wang Y.-S., Giaccone G.
Proc. Natl. Acad. Sci. U.S.A. 107:13040-13045(2010).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.
Heymach J.V.
Cancer Discov. 2:798-811(2012).
Genome-wide identification of genes with amplification and/or fusion in small cell lung cancer.
Yokota J.
Genes Chromosomes Cancer 52:802-816(2013).
Analysis of TP53 mutation status in human cancer cell lines: a reassessment.
Soussi T.
Hum. Mutat. 35:756-765(2014).
A comprehensive transcriptional portrait of human cancer cell lines.
Settleman J., Seshagiri S., Zhang Z.-M.
Nat. Biotechnol. 33:306-312(2015).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
OncoImmunology 3:e954893.1-e954893.12(2014).
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Golub T.R., Root D.E., Hahn W.C.
Sci. Data 1:140035-140035(2014).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).